Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Patients With Presumed Nonalcoholic Steatohepatitis (NASH)

NCT03823703 is registered in ClinicalTrials.gov with Corcept Therapeutics as lead sponsor.

NCT NCT03823703
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03823703 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Patients With Presumed Nonalcoholic Steatohepatitis (NASH)
Lead sponsor
Corcept Therapeutics
Phase
Phase 2
Overall status
Terminated
Start date
November 4, 2020
Completion date
April 5, 2021
Enrollment
12 (actual)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

nonalcoholic steatohepatitis (nash)